Document Detail


Intrasilicone bevacizumab injection for iris neovascularization after vitrectomy for proliferative diabetic retinopathy.
MedLine Citation:
PMID:  22986803     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To evaluate the efficacy and safety of intrasilicone injection of bevacizumab for the treatment of iris neovascularization after vitrectomy for proliferative diabetic retinopathy.
METHODS: Bevacizumab 1.25 mg/0.05 ml was injected into silicone oil in 15 eyes of 11 patients with iris neovascularization which had developed 2.5-6 months after vitrectomy and silicone oil tamponade. The main outcome measures were regression of iris neovascularization, intraocular pressure elevation, and visual acuity.
RESULTS: In all eyes, iris neovascularization regressed and postinjection intraocular pressure was controlled within 7 days postinjection. Visual acuity improved in 12 eyes. In 4 patients, iris neovascularization recurred within 10 weeks after the injection and they were successfully treated with a second intrasilicone bevacizumab injection of the same dose.
CONCLUSION: Intrasilicone injection of bevacizumab is safe and effective in the treatment of patients with iris neovascularization after vitrectomy for advanced proliferative diabetic retinopathy. Further studies on greater numbers of patients and more advanced neovascularization are recommended.
Authors:
Abdelrahman G Salman
Related Documents :
23147303 - Subconjunctival injection of triamcinolone for the treatment of upper lid retraction as...
22463493 - Internight sleep variability: its clinical significance and responsiveness to treatment...
3410553 - Workers' sleep quality as determined by shift system and demographic factors.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-09-13
Journal Detail:
Title:  Ophthalmic research     Volume:  49     ISSN:  1423-0259     ISO Abbreviation:  Ophthalmic Res.     Publication Date:  2013  
Date Detail:
Created Date:  2012-12-21     Completed Date:  2013-05-23     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0267442     Medline TA:  Ophthalmic Res     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  20-4     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 S. Karger AG, Basel.
Affiliation:
Ain Shams University, Cairo, Egypt. ab_gab@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angiogenesis Inhibitors / administration & dosage*
Antibodies, Monoclonal, Humanized / administration & dosage*
Diabetic Retinopathy / surgery
Female
Humans
Injections, Intraocular
Intraocular Pressure
Iris / blood supply*
Iris Diseases / drug therapy*,  etiology
Male
Middle Aged
Neovascularization, Pathologic / drug therapy*,  etiology
Prospective Studies
Silicone Oils / administration & dosage*
Visual Acuity
Vitrectomy / adverse effects*
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 0/Silicone Oils; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Are Knee and Foot Orthopedic Problems More Disabling in the Superobese?
Next Document:  Validation of continuous and noninvasive hemoglobin monitoring by pulse CO-oximetry in Japanese surg...